Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality
Feng Zhou,Ye-Mao Liu,Jing Xie,Haomiao Li,Fang Lei,Huilin Yang,Juan-Juan Qin,Jingjing Cai,Xiao-Jing Zhang,Bin Wu,Meng Xia,Da Xiang,Chengzhang Yang,Xinliang Ma,Qingbo Xu,Zhigang Lu,Haofeng Lu,Xigang Xia,Daihong Wang,Xiaofeng Liao,Gang Peng,Jun Yang,Xiaodong Huang,Bing-Hong Zhang,Yufeng Yuan,Xiang Wei,Peter P. Liu,Yibin Wang,Peng Zhang,Zhi-Gang She,Jiahong Xia,Hongliang Li
DOI: https://doi.org/10.1161/hypertensionaha.120.15622
IF: 9.8968
2020-07-14
Hypertension
Abstract:Treating coronavirus disease 2019 (COVID-19) using ACE (angiotensin-converting enzyme) inhibitors and angiotensin II receptor blockers (ARBs) is a clinical dilemma due to the perceived risk of exacerbating COVID-19 by elevating ACE2 expression. 1 Despite recent studies showing no harm to continue ACE inhibitors/ARBs in the setting of COVID-19, 2 , 3 it is still unknown whether ACE inhibitors and ARBs have equivalent impacts on COVID-19 mortality among patients preexisting different indications. To address this critical question, in this multi-centered retrospective study, we enrolled 15 504 participants diagnosed as COVID-19 and admitted to 17 hospitals located at Hubei Province, China, from December 31, 2019 to April 21, 2020. A total of 3572 eligible participants (aged 66 [interquartile range, 58–72] years, 51.1% male sex) with ACE inhibitors/ARBs indications and hospitalized due to COVID-19 were included in our analysis, whereas patients without taking any drugs for treating ACE inhibitors/ARBs indications or recorded hypotension shock within 24 hours after admission were excluded ( Figure [A]). Data collection, extraction, and analysis were conducted in a standard procedure by a team of physicians, analysts, and statisticians. The study design and procedures were approved by the central ethics committee and were accepted or approved by the local ethics committees of all participating hospitals. Informed consent forms were waived by each ethics committee. The data that support the findings of this study are available from the corresponding author upon reasonable request. Download figure Download PowerPoint Figure. The flowchart of patient enrollment and the associations of ACE (angiotensin-converting enzyme) inhibitors and angiotensin II receptor blockers (ARBs) with 28-d all-cause death of coronavirus disease 2019 (COVID-19). A , Flow chart of enrolling patients in this study. B , Forest plots showing the associations of in-hospital use of ACE inhibitors/ARBs vs non-ACE inhibitors/ARBs with 28-d all-cause death of COVID-19 among patients with different indications. C , Kaplan-Meier curves showing percent survivals in ACE inhibitors/ARBs and non-ACE inhibitors/ARBs groups among patients with all ACE inhibitors/ARBs indications. The blips indicate censoring. D , Forest plots showing the comparative associations of inpatients receiving ACE inhibitors or ARBs or other therapeutic agents with 28-d death of COVID-19 among patients having indications for taking ACE inhibitors/ARBs. E , Kaplan-Meier curves showing percent survival among patients in ARBs/ARBs groups during 28 d after admission. The blips indicate censoring. ACEI indicates ACE inhibitors; CAD, coronary artery disease; EMR, electronic medical records; HYP, hypertension; and PSM, propensity score–matched. We analyzed the associations between in-hospital use of ACE inhibitors/ARBs and 28-day all-cause death of COVID-19 compared to the use of non-ACE inhibitors/ARBs agents using propensity score–matched analysis where age, sex, disease severity, comorbidities, and calcium channel blockers medication usage were matched. And 906 ACE inhibitors/ARBs treated subjects were successfully matched with 1812 subjects treated with non-ACE inhibitors/ARBs agents during hospitalization at a ratio of 1:2. After further adjusting for imbalanced variables and in-hospital medications, the in-hospital use of ACE inhibitors/ARBs was significantly associated with lower risk of 28-day all-cause mortality of COVID-19 (adjusted hazard ratio [HR], 0.39 [95% CI, 0.26–0.58]; P <0.001) compared with the non-ACE inhibitors/ARBs group. Notably, patients in the ACE inhibitors/ARBs groups had significantly lower risk of 28-day all-cause mortality of COVID-19 among patients with hypertension (adjusted HR, 0.32 [95% CI, 0.15–0.66]; P =0.002), hypertension combined with coronary artery disease (adjusted HR, 0.11 [95% CI, 0.04–0.31]; P <0.001), and coronary artery disease (adjusted HR, 0.38 [95% CI, 0.16–0.89]; P =0.03; Figure [B ] and [C ]). Thus, patients with hypertension and coronary artery disease might obtain benefits from taking ACE inhibitors/ARBs compared with the non-ACE inhibitors/ARBs in the setting of COVID-19. Although ACE inhibitors and AR -Abstract Truncated-
peripheral vascular disease